MarketCap
Facebook
X
Telegram
Edwards Lifesciences Corporation Cash Flow 2025-2007 | EW
Brief overview of Edwards Lifesciences Corporation's cash movements
Cash flows are assessed across five available annual periods spanning 2021 to 2025.
Operating cash flow changed -7.9%, from $1.7 billion to $1.6 billion. The scale of cash generation barely increased.
Core operations generated cash in every available annual observation. Stability was high.
Operating cash flow to net income is 0.62x. Cash confirmation of reported profit appears insufficient.
Operating cash flow margin declined from 33.1% to 26.3%. Revenue converted into cash less effectively.
Working capital needs increased $453.9 million, or 7.5% of sales. This may restrain cash conversion.
Overall assessment
Edwards Lifesciences Corporation's cash flow is not clear-cut. Operating receipts exist, but their stability or the residual after investment needs attention.
Annual Cash Flow Edwards Lifesciences Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
1.6 B | 542 M | 896 M | 1.22 B | 1.73 B | 1.05 B | 1.18 B | 927 M | 1 B | 704 M | 550 M | - | - | - | - | 251 M | 165 M | 153 M | - |
Depreciation & Amortization |
157 M | 155 M | 145 M | 140 M | 135 M | 107 M | 89.3 M | 77.4 M | 81.9 M | 71.2 M | 65.8 M | 68.6 M | 62.9 M | 53.7 M | 58 M | 56.5 M | 58.7 M | 55.6 M | - |
Accounts Payables |
228 M | 197 M | 187 M | 202 M | 204 M | 196 M | 180 M | 134 M | 117 M | 97.1 M | 63.9 M | 58.2 M | 48.4 M | 74.7 M | 85 M | 47.6 M | 51.1 M | - | - |
Accounts Receivables |
660 M | 609 M | 772 M | 643 M | 582 M | 515 M | 544 M | 457 M | 422 M | 366 M | 315 M | 288 M | 302 M | 321 M | 284 M | 277 M | 249 M | - | - |
Total Inventories |
1.13 B | 1.09 B | 904 M | 876 M | 727 M | 802 M | 641 M | 607 M | 555 M | 397 M | 340 M | 297 M | 309 M | 281 M | 261 M | 204 M | 166 M | - | - |
All numbers in USD currency
Quarterly Cash Flow Edwards Lifesciences Corporation
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q3 | 2010-Q2 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
43.8 M | - | - | 280 M | - | - | - | -53.5 M | - | - | - | 314 M | - | 935 M | - | 293 M | - | 1.36 B | - | 300 M | - | 654 M | 438 M | 207 M | - | 780 M | 343 M | 1.5 M | - | 634 M | 292 M | 151 M | - | 637 M | 326 M | 128 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 14.9 M | 157 M | 61 M |
Depreciation & Amortization |
40.9 M | - | - | 36.6 M | - | - | - | 38.5 M | - | - | - | 35.2 M | - | 104 M | - | 34.7 M | - | 102 M | - | 32.4 M | - | 74.6 M | 49 M | 24.5 M | - | 65.4 M | 42.3 M | 20.6 M | - | 57.5 M | 38.3 M | 19.1 M | - | 60.7 M | 40 M | 21.1 M | - | 52.1 M | 33.9 M | 15.9 M | - | 51.3 M | 32.8 M | 16 M | - | 50.3 M | 32.3 M | 16.2 M | - | 45.8 M | 28.8 M | 14.1 M | - | 42.2 M | 27.8 M | 13.8 M | - | 43.2 M | 29.3 M | 14.5 M | 41.1 M | 27.7 M |
Accounts Payables |
181 M | 165 M | 162 M | 172 M | 197 M | 173 M | 186 M | 212 M | 187 M | 191 M | 193 M | 181 M | 202 M | 155 M | - | 159 M | 204 M | 140 M | 145 M | 150 M | 196 M | 196 M | 196 M | 196 M | 180 M | 180 M | 180 M | 180 M | 134 M | 134 M | 134 M | 134 M | 117 M | 117 M | 117 M | 117 M | 97.1 M | 97.1 M | 97.1 M | 97.1 M | 63.9 M | 63.9 M | 63.9 M | 63.9 M | 58.2 M | 58.2 M | 58.2 M | 58.2 M | 48.4 M | 48.4 M | - | - | 74.7 M | - | - | - | 85 M | - | - | - | - | - |
Accounts Receivables |
776 M | 693 M | 697 M | 669 M | 609 M | 716 M | 778 M | 818 M | 772 M | 740 M | 754 M | 718 M | 643 M | 618 M | - | 636 M | 582 M | 601 M | 640 M | 587 M | 515 M | 515 M | 515 M | 515 M | 544 M | 544 M | 610 M | 599 M | 457 M | 424 M | 431 M | 407 M | 439 M | 439 M | 439 M | 422 M | 366 M | 454 M | 415 M | 415 M | 315 M | 338 M | 344 M | 344 M | 288 M | 323 M | 325 M | 325 M | 302 M | 328 M | 328 M | 328 M | 321 M | 325 M | 336 M | 347 M | 321 M | 347 M | 321 M | 321 M | 303 M | 294 M |
Total Inventories |
1.12 B | 1.14 B | 1.14 B | 1.11 B | 1.09 B | 1.1 B | 1.02 B | 1.21 B | 904 M | 1.03 B | 980 M | 914 M | 876 M | 758 M | - | 731 M | 727 M | 738 M | 760 M | 768 M | 802 M | 802 M | 802 M | 802 M | 641 M | 641 M | 641 M | 641 M | 607 M | 607 M | 607 M | 607 M | 555 M | 555 M | 555 M | 555 M | 397 M | 397 M | 397 M | 397 M | 340 M | 340 M | 340 M | 340 M | 297 M | 297 M | 297 M | 297 M | 309 M | 309 M | 309 M | 309 M | 281 M | 281 M | 281 M | 281 M | 261 M | 261 M | 261 M | 261 M | 212 M | 182 M |
All numbers in USD currency
Cash Flow Statement is one of the three key financial reports of the company Edwards Lifesciences Corporation, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.
Main Sections of the Cash Flow Statement- Operating Activities
This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash. - Investing Activities
Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign. - Financing Activities
Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.
The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.
USA
France
Canada
Australia
Britain
